Medtronic Banking On S670 Stent, Pipeline For Vascular Business Rebound
This article was originally published in The Gray Sheet
Executive Summary
U.S. feasibility trials of Medtronic's INX neurovascular stent for the treatment of atherosclerotic vessels in the brain began Aug. 11, the company announced Aug. 23.
You may also be interested in...
Medtronic Entering $450 Mil. ENT Market Via $800 Mil. Xomed Acquisition
Acquisition of surgical ear nose and throat device maker Xomed Surgical Products under an Aug. 27 merger agreement valued at $800 mil. will mark Medtronic's entrance into the $450 mil. worldwide ENT market.
Medtronic Entering $450 Mil. ENT Market Via $800 Mil. Xomed Acquisition
Acquisition of surgical ear nose and throat device maker Xomed Surgical Products under an Aug. 27 merger agreement valued at $800 mil. will mark Medtronic's entrance into the $450 mil. worldwide ENT market.
Medtronic v. Tyco
California federal district court grants preliminary injunction against spinal fusion cage rival Surgical Dynamics (a division of Tyco's U.S. Surgical business) prohibiting it from selling its Ray TFC spinal implant fusion cage. Medtronic alleges that the device infringes patents for its Inter Fix threaded spinal fusion device. The injunction, which was announced Aug. 16 and reinforces an April 16 federal appeals court reversal in Medtronic's favor (1"The Gray Sheet" May 3, p. 19), is temporary pending completion of patent validity trial proceedings